NCT00623259

Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects

Phase I Vaccination Study Testing the Safety and Reactogenicity of a Recombinant MVA HIV Multiantigen Vaccine (MVA-mBN120B) in HIV-infected Subjects With CD4 Count > 350/µL

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Bavarian Nordic · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

Monocentric study to assess the safety and immunogenicity of the recombinant MVA-HIV multiantigen vaccine MVA-mBN120B in HIV-infected subjects. 15 subjects will receive immunizations at day 0, after 4 and 12 weeks at a dose of 2E8 TCID50 MVA-mBN120B. The vaccine will be administered subcutaneously.

Conditions

• HIV Infections

Interventions

Type	Name	Description
BIOLOGICAL	MVA-mBN120B

Timeline

• Start date: 2008-05-01
• Primary completion: 2009-02-01
• Completion: 2009-04-01
• First posted: 2008-02-26
• Last updated: 2010-05-20

Locations

1 site across 1 country: United States